These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. Witt DA; Donson AM; Amani V; Moreira DC; Sanford B; Hoffman LM; Handler MH; Levy JMM; Jones KL; Nellan A; Foreman NK; Griesinger AM Pediatr Blood Cancer; 2018 May; 65(5):e26960. PubMed ID: 29350470 [TBL] [Abstract][Full Text] [Related]
4. C11orf95-RELA fusions and upregulated NF-KB signalling characterise a subset of aggressive supratentorial ependymomas that express L1CAM and nestin. Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Rajeshwari M; Singh M; Suri V; Sarkar C; Sharma MC J Neurooncol; 2018 May; 138(1):29-39. PubMed ID: 29354850 [TBL] [Abstract][Full Text] [Related]
5. C11orf95-RELA reprograms 3D epigenome in supratentorial ependymoma. Zhu JJ; Jillette N; Li XN; Cheng AW; Lau CC Acta Neuropathol; 2020 Dec; 140(6):951-960. PubMed ID: 32909151 [TBL] [Abstract][Full Text] [Related]
7. L1CAM Immunopositivity in Anaplastic Supratentorial Ependymomas: Correlation With Clinical and Histological Parameters. Chavali P; Rao S; Palavalasa S; Bevinahalli N; Muthane YTC; Sadashiva N; Santosh V Int J Surg Pathol; 2019 May; 27(3):251-258. PubMed ID: 30251576 [TBL] [Abstract][Full Text] [Related]
8. epi-Aszonalenin B from Aspergillus novofumigatus inhibits NF-κB activity induced by ZFTA-RELA fusion protein that drives ependymoma. Ishikawa K; Ishii M; Yaguchi T; Katada T; Ichinose K; Ohata S Biochem Biophys Res Commun; 2022 Mar; 596():104-110. PubMed ID: 35131506 [TBL] [Abstract][Full Text] [Related]
9. A novel type of C11orf95-LOC-RELA fusion in a grade II supratentorial ependymoma: report of a case with literature review. de Sousa GR; Marie SKN; Oba-Shinjo SM; Ramalho LNZ; Tone LG; Valera ET Childs Nerv Syst; 2019 Apr; 35(4):689-694. PubMed ID: 30631904 [TBL] [Abstract][Full Text] [Related]
10. Molecular subgrouping of ependymoma across three anatomic sites and their prognostic implications. Chinnam D; Gupta K; Kiran T; Saraswati A; Salunke P; Madan R; Kumar N; Radotra BD Brain Tumor Pathol; 2022 Jul; 39(3):151-161. PubMed ID: 35348910 [TBL] [Abstract][Full Text] [Related]
11. Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma. Tzaridis T; Milde T; Pajtler KW; Bender S; Jones DT; Müller S; Wittmann A; Schlotter M; Kulozik AE; Lichter P; Peter Collins V; Witt O; Kool M; Korshunov A; Pfister SM; Witt H Oncotarget; 2016 Sep; 7(38):61860-61873. PubMed ID: 27556362 [TBL] [Abstract][Full Text] [Related]
12. CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort. Jünger ST; Andreiuolo F; Mynarek M; Wohlers I; Rahmann S; Klein-Hitpass L; Dörner E; Zur Mühlen A; Velez-Char N; von Hoff K; Warmuth-Metz M; Kortmann RD; Timmermann B; von Bueren A; Rutkowski S; Pietsch T Acta Neuropathol; 2020 Sep; 140(3):405-407. PubMed ID: 32514758 [No Abstract] [Full Text] [Related]
13. Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors. Fukuoka K; Kanemura Y; Shofuda T; Fukushima S; Yamashita S; Narushima D; Kato M; Honda-Kitahara M; Ichikawa H; Kohno T; Sasaki A; Hirato J; Hirose T; Komori T; Satomi K; Yoshida A; Yamasaki K; Nakano Y; Takada A; Nakamura T; Takami H; Matsushita Y; Suzuki T; Nakamura H; Makino K; Sonoda Y; Saito R; Tominaga T; Matsusaka Y; Kobayashi K; Nagane M; Furuta T; Nakada M; Narita Y; Hirose Y; Ohba S; Wada A; Shimizu K; Kurozumi K; Date I; Fukai J; Miyairi Y; Kagawa N; Kawamura A; Yoshida M; Nishida N; Wataya T; Yamaoka M; Tsuyuguchi N; Uda T; Takahashi M; Nakano Y; Akai T; Izumoto S; Nonaka M; Yoshifuji K; Kodama Y; Mano M; Ozawa T; Ramaswamy V; Taylor MD; Ushijima T; Shibui S; Yamasaki M; Arai H; Sakamoto H; Nishikawa R; Ichimura K; Acta Neuropathol Commun; 2018 Dec; 6(1):134. PubMed ID: 30514397 [TBL] [Abstract][Full Text] [Related]
14. Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging. Pagès M; Pajtler KW; Puget S; Castel D; Boddaert N; Tauziède-Espariat A; Picot S; Debily MA; Kool M; Capper D; Sainte-Rose C; Chrétien F; Pfister SM; Pietsch T; Grill J; Varlet P; Andreiuolo F Brain Pathol; 2019 May; 29(3):325-335. PubMed ID: 30325077 [TBL] [Abstract][Full Text] [Related]
15. Clinicopathological evaluation of PD-L1 expression and cytotoxic T-lymphocyte infiltrates across intracranial molecular subgroups of ependymomas: are these tumors potential candidates for immune check-point blockade? Nambirajan A; Malgulwar PB; Sharma A; Boorgula MT; Doddamani R; Singh M; Suri V; Sarkar C; Sharma MC Brain Tumor Pathol; 2019 Oct; 36(4):152-161. PubMed ID: 31388782 [TBL] [Abstract][Full Text] [Related]
16. Activation of Hedgehog signaling by the oncogenic RELA fusion reveals a primary cilia-dependent vulnerability in supratentorial ependymoma. de Almeida Magalhães T; Alencastro Veiga Cruzeiro G; Ribeiro de Sousa G; Englinger B; Fernando Peinado Nagano L; Ancliffe M; Rodrigues da Silva K; Jiang L; Gojo J; Cherry Liu Y; Carline B; Kuchibhotla M; Pinto Saggioro F; Kazue Nagahashi Marie S; Mieko Oba-Shinjo S; Andres Yunes J; Gomes de Paula Queiroz R; Alberto Scrideli C; Endersby R; Filbin MG; Silva Borges K; Salic A; Gonzaga Tone L; Valera ET Neuro Oncol; 2023 Jan; 25(1):185-198. PubMed ID: 35640920 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of the NOTCH pathway using γ-secretase inhibitor RO4929097 has limited antitumor activity in established glial tumors. Dantas-Barbosa C; Bergthold G; Daudigeos-Dubus E; Blockus H; Boylan JF; Ferreira C; Puget S; Abely M; Vassal G; Grill J; Geoerger B Anticancer Drugs; 2015 Mar; 26(3):272-83. PubMed ID: 25486598 [TBL] [Abstract][Full Text] [Related]